Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 83, Issue 4, Pages 693-704Publisher
SPRINGER
DOI: 10.1007/s00280-019-03780-y
Keywords
Dabrafenib; Trametinib; BRAF V600 melanoma; Pharmacokinetics; Pyrexia; Cytokines
Categories
Funding
- University of Sydney
- Novartis
Ask authors/readers for more resources
PurposeThe combination of a BRAF inhibitor dabrafenib and a MEK inhibitor trametinib (CombiDT) has improved outcomes compared with chemotherapy or BRAF inhibitor monotherapy in advanced BRAF V600E/K melanoma. However, CombiDT causes a high incidence of pyrexia and treatment interruptions. Pharmacokinetic analysis may provide an explanation for the pyrexia.Methods34 patients with Stage 3 BRAF V600 melanoma were treated with CombiDT on a clinical trial between August 2014 and June 2017. Plasma concentrations of drugs and metabolites were determined using validated LC-MS assays, in addition to analysis of a panel of cytokines.ResultsPyrexia was experienced by 71% of the patients, with an additional 17% requiring dose interruption related to a pyrexia-like prodrome. Dabrafenib concentrations ranged from 4.0 to 4628ng/ml and trametinib from 1.0 to 45ng/ml in 34 patients. N-desmethyl-dabrafenib was the most prevalent metabolite, followed by carboxy- and hydroxy-dabrafenib. No definitive association between pyrexia and AUC or C-min of the drugs, or metabolites could be observed. The level of IL-1B at the early during treatment (EDT) (as a % of pre-treatment) was higher in the pyrexia group (median 109% (range 32-681%) than in the no-incidence group [56% (26-79%)] (p=0.029). Similarly, the level of IL-6at EDT was higher in the pyrexia group [181% (34-3156%) vs 73% (57-101%)] (p=0.028).ConclusionsNo apparent associations between pyrexia and exposure to the drugs or metabolites could be observed. Greater elevations in IL-1B and IL-6 were observed in patients with pyrexia during the first week of treatment compared to those without pyrexia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available